News & Videos - ANGLE ORD 10P

Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that the European Patent Office has granted a European Patent for its innovative CellKeep™...

REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGY Paper published in the journal "Current Issues in Molecular Biology" special issue: advanced solutions for cancer therapy GUILDFORD, SURREY / ACCESSWIRE / January 22, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is pleased to...

USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERY Harvested CTCs reveal gene expression profile associated with development and progression of brain metastasis in melanoma Researchers suggest such profiling could prove to be "pivotal" to prescribing more targeted treatments in this setting GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC)...

GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is pleased to announce that Berenberg will act as the Company's Nominated Adviser and Sole Broker with immediate effect. For further information: ANGLE plc Andrew Newland, Chief Executive Ian Griffiths, Finance Director +44 (0) 1483 343434...

ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIES ANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to investigate real-time patient PD-L1 status for clinical studies The test is designed for highly accurate, repeatable, and precise results for CTC PD-L1 biomarker expression GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for...

RESEARCH DEMONSTRATES POTENTIAL OF THE PARSORTIX SYSTEM TO SUPPORT POWERFUL CHARACTERISATION OF CTCS IN HEAD AND NECK CANCER 41 key biomarkers including the immune checkpoint proteins PD-L1, CTLA4 and CD39 successfully evaluated Providing key information which could support the development of personalised treatment strategies in HNSCC GUILDFORD, SURREY / ACCESSWIRE / October 25, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell...

Interim Results for the six months ended 30 June 2023 BUILDING COMMERCIAL MOMENTUM DELIVERS REVENUE GROWTH Cash runway extended into Q1 2025 GUILDFORD, SURREY / ACCESSWIRE / September 7, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology market, today announces its unaudited interim financial results for the six months ended 30 June 2023. Financial Highlights...

GUILDFORD, SURREY / ACCESSWIRE / June 28, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Andrew Holder, Head of Investor Relations Berenberg (NOMAD and Joint Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 Jefferies...

Brett Swansiger joins as Chief Commercial Officer Karen Miller PhD joins as Chief Scientific Officer GUILDFORD, SURREY / ACCESSWIRE / June 5, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the appointments of Brett Swansiger as Chief Commercial Officer (CCO) and Karen Miller PhD as Chief Scientific Officer (CSO). The addition of these highly skilled and experienced leaders will further enhance ANGLE's management team and...

Pharma Services Contract Win Parsortix DNA Damage Response Assays developed by ANGLE to be used for exploratory objectives in a Phase 1 clinical trial Trial expected to complete by year end 2024 GUILDFORD, SURREY / ACCESSWIRE / May 25, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that its first bespoke assay development customer, Artios Pharma (Artios), has signed a new contract to utilise two DNA Damage Response assays developed by...

GUILDFORD, SURREY / ACCESSWIRE / May 22, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company announces that Garth Selvey has informed the Board of his intention to retire and leave ANGLE at the publication of the 2023 Interims in September. Garth will hand over the Chair with immediate effect to Dr. Jan Groen, currently an independent Non-executive Director on the Board. Garth joined ANGLE as a Non-executive Director in 2006 and became Chairman in 2007. Under his...

Preliminary Results for the year ended 31 December 2022 FDA CLEARANCE A MAJOR BREAKTHROUGH FOR PARSORTIX LIQUID BIOPS Parsortix system substantially out-performs standard of care for ovarian cancer diagnosis Prostate cancer partnership signed with Solaris Health Pipeline of opportunities growing strongly GUILDFORD, SURREY / ACCESSWIRE / April 21, 2023 / ANGLE plc (OTCQX:ANPCY)(AIM:AGL), a world-leading liquid biopsy company, today announces audited preliminary results for the year ended 31...

PARSORTIX POSTER PRESENTED AT AACR ANNUAL MEETING 2023 Study demonstrates the feasibility of combining IF and HER2 FISH analysis with CTCs harvested using the Parsortix system Capability to measure HER2 protein overexpression on CTCs using ANGLE's Portrait Flex assay opens up substantial pharma and clinical market opportunities GUILDFORD, UK / ACCESSWIRE / April 17, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the presentation of a poster...

Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / April 3, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2022 on Friday 21 April 2023. A virtual meeting and webcast for analysts will be held at 10:00 am BST on Friday 21 April 2023. If you wish to attend, please register in advance and log on to the webcast approximately 5 minutes before 10:00 am on the day of the...

GUILDFORD, UK / ACCESSWIRE / March 10, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 30 June 2021 ("the Remuneration Policy"), the Remuneration Committee has approved the grant under the Long-Term Incentive Plan (LTIP) of options (the "LTIP Options") over a maximum of 6,000,000 ordinary shares of £0.10 ("Ordinary Shares"), subject to the performance...

GUILDFORD, SURREY / ACCESSWIRE / March 9, 2023 / TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : ANGLE plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark...

Director/PDMR shareholding GUILDFORD, SURREY / ACCESSWIRE / February 9, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, on 09 February 2023, it has been notified that Andrew Newland, Chief Executive Officer, purchased 125,000 ordinary shares of 10 pence each ("Ordinary Shares") at a price of 28.75 pence each. The Company was also notified that Ian Griffiths, Finance Director, purchased 30,000 Ordinary Shares via his self-invested...

Joseph Eid M.D., is a US certified medical oncologist with extensive experience of the use of biomarkers in clinical trials and as companion diagnostics Previous roles include senior positions in oncology at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche GUILDFORD, SURREY / ACCESSWIRE / January 19, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that Joseph (Joe) Eid M.D. has been appointed as a Non-Executive Director of the...

GUILDFORD, SURREY / ACCESSWIRE / January 11, 2023 / TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : ANGLE plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please...

TWO PARSORTIX POSTERS PRESENTED AT LEADING BREAST CANCER CONFERENCE Studies demonstrate the utility of the Parsortix PC1 Clinical System to isolate and harvest CTCs from metastatic breast cancer patients for further downstream analysis Harvested CTCs underwent cytological, immunofluorescent and molecular downstream evaluation GUILDFORD, SURREY / ACCESSWIRE / December 12, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the presentation of two...